Cogent Biosciences, Inc. financial data

Symbol
COGT on Nasdaq
Industry
Pharmaceutical Preparations
Location
275 Wyman Street, 3 Rd Floor, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Unum Therapeutics Inc. (to 10/5/2020), Unum Therapeutics, Inc. (to 3/30/2018)
Latest financial report
10-K - Q4 2024 - Feb 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 782 % -16.2%
Debt-to-equity 18.4 % +8.68%
Return On Equity -74.9 % -10.2%
Return On Assets -63.3 % -8.85%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 114M shares +19.1%
Common Stock, Shares, Outstanding 110M shares +28.3%
Entity Public Float 869M USD -10.2%
Common Stock, Value, Issued 110K USD +27.9%
Weighted Average Number of Shares Outstanding, Basic 104M shares +30.4%
Weighted Average Number of Shares Outstanding, Diluted 104M shares +30.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 233M USD +33.9%
General and Administrative Expense 43.3M USD +25.9%
Costs and Expenses 276M USD +32.6%
Operating Income (Loss) -276M USD -32.6%
Nonoperating Income (Expense) 20.1M USD +27.7%
Net Income (Loss) Attributable to Parent -256M USD -33%
Earnings Per Share, Basic -1.94 USD/shares 0%
Earnings Per Share, Diluted -1.94 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 98.2M USD +84.4%
Assets, Current 296M USD +9.49%
Property, Plant and Equipment, Net 6.47M USD -22.5%
Operating Lease, Right-of-Use Asset 20.1M USD -8.64%
Other Assets, Noncurrent 4.86M USD -0.04%
Assets 328M USD +4.61%
Accounts Payable, Current 12M USD +12.7%
Employee-related Liabilities, Current 12.3M USD +24.2%
Liabilities, Current 55.7M USD +46%
Operating Lease, Liability, Noncurrent 15.9M USD -8.96%
Liabilities 71.6M USD +28.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 447K USD +81.7%
Retained Earnings (Accumulated Deficit) -859M USD -42.4%
Stockholders' Equity Attributable to Parent 256M USD -0.59%
Liabilities and Equity 328M USD +4.61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.5M USD -32.9%
Net Cash Provided by (Used in) Financing Activities 214M USD +48003%
Net Cash Provided by (Used in) Investing Activities 1.04M USD -98.3%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 110M shares +28.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 163M USD +681%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98.2M USD +84.4%
Deferred Tax Assets, Valuation Allowance 219M USD +39.1%
Operating Lease, Liability 17.5M USD -7.35%
Payments to Acquire Property, Plant, and Equipment 70K USD -93.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -256M USD -33.1%
Lessee, Operating Lease, Liability, to be Paid 25.2M USD -9.92%
Property, Plant and Equipment, Gross 12.6M USD +4.77%
Operating Lease, Liability, Current 1.57M USD +12.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.7M USD -5.07%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.84M USD +2.19%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.77M USD -15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.13M USD -20.9%
Deferred Tax Assets, Operating Loss Carryforwards 64.3M USD +34.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.18M USD +2.21%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 39.7M USD +29.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%